1
|
Meyer S, Langer J, Poryo M, Bay JG, Wagenpfeil S, Heinrich B, Nunold H, Strzelczyk A, Ebrahimi-Fakhari D. Epileptic Status in a PEDiatric cohort (ESPED) requiring intensive care treatment: A multicenter, national, two-year prospective surveillance study. Epilepsia Open 2023. [PMID: 36764666 DOI: 10.1002/epi4.12707] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2022] [Accepted: 01/25/2023] [Indexed: 02/12/2023] Open
Abstract
OBJECTIVE The aim of this study was to provide seizure etiology, semiology, underlying conditions, and out-of- and in-hospital diagnostics, treatment, and outcome data on children with out-of- or in-hospital-onset status epilepticus (SE) according to the International League Against Epilepsy definition that required admission to the pediatric intensive care unit (PICU) for ≥4 hours. METHODS This prospective national surveillance study on SE in childhood and adolescence was conducted over 2 years (07/2019-06/2021). RESULTS This study examined 481 SE episodes in 481 children with a median age of 43 months (1 month to 17 years 11 months), of which 46.2% were female and 50.7% had a previous seizure history. The most frequent acute SE cause was a prolonged, complicated febrile seizure (20.6%). The most common initial seizure types were generalized seizures (49.9%), focal seizures (18.0%), and unknown types (12.1%); 40.5% of patients suffered from refractory SE and 5.0% from super-refractory SE. The three most common medications administered by nonmedically trained individuals were diazepam, midazolam, and antipyretics. The three most frequent anti-seizure medications (ASMs) administered by the emergency physician were midazolam, diazepam, and propofol. The three most common ASMs used in the clinical setting were midazolam, levetiracetam, and phenobarbital. New ASMs administered included lacosamide, brivaracetam, perampanel, stiripentol, and eslicarbazepine. Status epilepticus terminated in 16.0% in the preclinical setting, 19.1% in the emergency department, and 58.0% in the PICU; the outcome was unknown for 6.9%. The median PICU stay length was 2 (1-121) days. The median modified Rankin scale was 1 (0-5) on admission and 2 (0-6) at discharge. New neurological deficits after SE were observed in 6.2%. The mortality rate was 3.5%. SIGNIFICANCE This study provides current real-world out-of- and in-hospital data on pediatric SE requiring PICU admission. New ASMs are more frequently used in this population. This knowledge may help generate a more standardized approach.
Collapse
Affiliation(s)
- Sascha Meyer
- Department of General Pediatrics and Neonatology, and Neuropediatrics, Saarland University Medical Center, Homburg, Germany.,Franz-Lust Klinik für Kinder und Jugendliche, Karlsruhe, Germany
| | - Jaro Langer
- Department of General Pediatrics and Neonatology, and Neuropediatrics, Saarland University Medical Center, Homburg, Germany
| | - Martin Poryo
- Department of Pediatric Cardiology and Pediatric Intensive Care Medicine, Saarland University Medical Center, Homburg, Germany
| | - Johannes Goaliath Bay
- Department of General Pediatrics and Neonatology, and Neuropediatrics, Saarland University Medical Center, Homburg, Germany
| | - Stefan Wagenpfeil
- Institute for Medical Biometry, Epidemiology and Medical Informatics, Saarland University, Homburg, Germany
| | - Beate Heinrich
- Erhebungseinheit für Seltene Pädiatrische Erkrankungen (ESPED), Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
| | - Holger Nunold
- Department of General Pediatrics and Neonatology, and Neuropediatrics, Saarland University Medical Center, Homburg, Germany
| | - Adam Strzelczyk
- Epilepsy Center Frankfurt Rhine-Main, Center of Neurology and Neurosurgery, Goethe-University and University Hospital Frankfurt, Frankfurt am Main, Germany.,Center for Personalized Translational Epilepsy Research (CePTER), Goethe-University Frankfurt, Frankfurt am Main, Germany
| | - Daniel Ebrahimi-Fakhari
- Department of General Pediatrics, University Children's Hospital Muenster, Muenster, Germany
| | -
- Department of General Pediatrics, University Children's Hospital Muenster, Muenster, Germany
| |
Collapse
|
2
|
Barloy L, Heinrich B, Scarpi-Luttenauer M, Douce L, Henry M, Khalil G, Klein D, Kyritsakas N, Mobian P. Modified pyridine-triazole and 2,2'-bipyrimidine ligands generating robust titanium complexes constructed around a TiO 4N 2 core. Dalton Trans 2021; 50:17008-17022. [PMID: 34738604 DOI: 10.1039/d1dt03172d] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The synthesis and characterisation of novel chelate nitrogen ligands with phasmidic tails (pyridine-triazole ligand 1b; 2,2'-bipyrimidine ligands 2b and 3b) as well as their titanium(IV) coordination complexes are reported. The analogous ligands 1a, 2a and 3a with methoxy substituents instead of the tails were also synthesized, together with titanium complexes that could be crystallographically characterised. A good agreement is noticed between analytical data of the complexes in solution (NMR) and in the solid state (X-ray diffraction). The complexes are overall robust on phases like alumina or silica, so that they could be characterised by TLC and sometimes chromatographied. Supramolecular architectures were generated from an equimolar solution of titanium(IV) isopropoxide, ligand 1a and a polyphenol ligand 5-H4, leading to a double-stranded helicate characterised by MS, NMR and crystallography, which was then converted into a trinuclear complex as shown by MS and NMR DOSY data. The liquid-crystalline behaviour of the ligands 1b, 2b and 3b incorporating the long alkyl tails and that of the complexes derived from these ligands have been investigated.
Collapse
Affiliation(s)
- L Barloy
- Université de Strasbourg, CNRS, CMC UMR 7140, F-67000 Strasbourg, France.
| | - B Heinrich
- Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS), UMR 7504, CNRS-Université de Strasbourg, F-67034 Strasbourg, France
| | | | - L Douce
- Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS), UMR 7504, CNRS-Université de Strasbourg, F-67034 Strasbourg, France
| | - M Henry
- Université de Strasbourg, CNRS, CMC UMR 7140, F-67000 Strasbourg, France.
| | - G Khalil
- Université de Strasbourg, CNRS, CMC UMR 7140, F-67000 Strasbourg, France.
| | - D Klein
- Université de Strasbourg, CNRS, CMC UMR 7140, F-67000 Strasbourg, France.
| | - N Kyritsakas
- Université de Strasbourg, CNRS, CMC UMR 7140, F-67000 Strasbourg, France.
| | - P Mobian
- Université de Strasbourg, CNRS, CMC UMR 7140, F-67000 Strasbourg, France.
| |
Collapse
|
3
|
Ebrahimi-Fakhari D, Mann LL, Poryo M, Graf N, von Kries R, Heinrich B, Ebrahimi-Fakhari D, Flotats-Bastardas M, Gortner L, Zemlin M, Meyer S. Correction to: Incidence of tuberous sclerosis and age at first diagnosis: new data and emerging trends from a national, prospective surveillance study. Orphanet J Rare Dis 2019; 14:106. [PMID: 31084624 PMCID: PMC6513511 DOI: 10.1186/s13023-019-1090-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2019] [Accepted: 05/07/2019] [Indexed: 11/30/2022] Open
Affiliation(s)
- Daniel Ebrahimi-Fakhari
- Department of Pediatric Neurology, Saarland University Medical Center, Building 9, Kirrberger Strasse, 66421, Homburg, Saarland, Germany.
| | - Lilian Lisa Mann
- Department of Pediatric Neurology, Saarland University Medical Center, Building 9, Kirrberger Strasse, 66421, Homburg, Saarland, Germany
| | - Martin Poryo
- Department of Pediatric Cardiology, Saarland University Medical Center, Homburg, Germany
| | - Norbert Graf
- Department of Pediatric Oncology and Hematology, Saarland University Medical Center, Homburg, Germany
| | - Rüdiger von Kries
- Division of Epidemiology, Institute of Social Pediatrics and Adolescent Medicine, Ludwig Maximilian's University, Munich, Germany.,German Paediatric Surveillance Unit (ESPED), Coordination Center for Clinical Studies, Heinrich Heine University, Düsseldorf, Germany
| | - Beate Heinrich
- German Paediatric Surveillance Unit (ESPED), Coordination Center for Clinical Studies, Heinrich Heine University, Düsseldorf, Germany
| | - Darius Ebrahimi-Fakhari
- Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Marina Flotats-Bastardas
- Department of Pediatric Neurology, Saarland University Medical Center, Building 9, Kirrberger Strasse, 66421, Homburg, Saarland, Germany
| | - Ludwig Gortner
- Department of Pediatric Neurology, Saarland University Medical Center, Building 9, Kirrberger Strasse, 66421, Homburg, Saarland, Germany
| | - Michael Zemlin
- Department of Pediatric Neurology, Saarland University Medical Center, Building 9, Kirrberger Strasse, 66421, Homburg, Saarland, Germany
| | - Sascha Meyer
- Department of Pediatric Neurology, Saarland University Medical Center, Building 9, Kirrberger Strasse, 66421, Homburg, Saarland, Germany
| |
Collapse
|
4
|
Barloy L, Heinrich B, Douce L, Henry M, Scarpi-Luttenauer M, Kyritsakas N, Mobian P. A robust Ti(iv)-based mesogen constructed around a TiO4N2 core. Dalton Trans 2019; 48:1960-1963. [DOI: 10.1039/c8dt04972f] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A Ti(iv)-complex with thermotropic liquid crystal properties is reported.
Collapse
Affiliation(s)
- L. Barloy
- Laboratoire de Chimie Moléculaire de l'Etat Solide
- UMR 7140 UDS-CNRS
- Université de Strasbourg
- F-67000 Strasbourg
- France
| | - B. Heinrich
- Université de Strasbourg
- CNRS
- Institut de Physique et de Chimie des Matériaux de Strasbourg
- F-67000 Strasbourg
- France
| | - L. Douce
- Université de Strasbourg
- CNRS
- Institut de Physique et de Chimie des Matériaux de Strasbourg
- F-67000 Strasbourg
- France
| | - M. Henry
- Laboratoire de Chimie Moléculaire de l'Etat Solide
- UMR 7140 UDS-CNRS
- Université de Strasbourg
- F-67000 Strasbourg
- France
| | - M. Scarpi-Luttenauer
- Laboratoire de Chimie Moléculaire de l'Etat Solide
- UMR 7140 UDS-CNRS
- Université de Strasbourg
- F-67000 Strasbourg
- France
| | - N. Kyritsakas
- Laboratoire de Tectonique Moléculaire
- UMR 7140 UDS-CNRS
- Université de Strasbourg
- F-67000 Strasbourg
- France
| | - P. Mobian
- Laboratoire de Chimie Moléculaire de l'Etat Solide
- UMR 7140 UDS-CNRS
- Université de Strasbourg
- F-67000 Strasbourg
- France
| |
Collapse
|
5
|
Ebrahimi-Fakhari D, Mann LL, Poryo M, Graf N, von Kries R, Heinrich B, Ebrahimi-Fakhari D, Flotats-Bastardas M, Gortner L, Zemlin M, Meyer S. Incidence of tuberous sclerosis and age at first diagnosis: new data and emerging trends from a national, prospective surveillance study. Orphanet J Rare Dis 2018; 13:117. [PMID: 30016967 PMCID: PMC6050673 DOI: 10.1186/s13023-018-0870-y] [Citation(s) in RCA: 63] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2018] [Accepted: 07/06/2018] [Indexed: 01/01/2023] Open
Abstract
Background Tuberous Sclerosis Complex (TSC) is a rare multisystem disorder. In 2012 diagnostic criteria for TSC were revised. However, data on the incidence of TSC are limited. Methods Prospective, national surveillance study in Germany over a 2-year-period (03/2015–02/2017) using current revised criteria for TSC. Patients up to the age of 18 years with a new diagnosis of definite or possible TSC (clinical and/or genetic) were included. The aims of this study were 1) to generate up-to-date data on the incidence of definite or possible TSC, 2) to assess age at first diagnosis, and 3) to compare these data with previous epidemiologic data. Results In total, 86 patients met inclusion criteria (definite or possible TSC) with a median age at diagnosis of 6 months (range: 5 months before birth – 197 months of age). Among patients identified with features of TSC, 73.3% met criteria for definite diagnosis (median age: 7 months) and 26.7% met criteria for a possible diagnosis (median age: 3 months). 55.8% of patients were male. When excluding prenatally diagnosed patients, median age at diagnosis was 11 months with a range of 0 to 197 months. The 3 most common clinical features at diagnosis of TSC were central nervous system involvement in 73.3% patients (of these 95.2% experienced seizures), cutaneous involvement in 58.1% patients (with the most common lesion being hypomelanotic macules in 92%) and cardiac rhabdomyoma in half of the patients. Cardiac rhabdomyoma were detected by prenatal ultrasonography in 22.1% of patients. The presence of cardiac rhabdomyoma was associated with cardiac arrhythmias in 25.6% (about 13% of all diagnosed patients) in our cohort. The overall prevalence of seizure disorders was 69.8%. The annual incidence rate of TSC is estimated at a minimum of 1:17.785 live births. However correcting for underreporting, the estimated incidence rate of definite or possible TSC is approximately 1:6.760–1:13.520 live births in Germany. Conclusions This is the first study that assessed prospectively the incidence rate of TSC in children and adolescents using the updated diagnostic criteria of 2012. This prospective surveillance study demonstrates a low age at first diagnosis (median: 6 months), likely due to antenatal detection of cardiac rhabdomyoma. Early diagnosis bears the potential for implementing effective therapies at an earlier stage. Electronic supplementary material The online version of this article (10.1186/s13023-018-0870-y) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Daniel Ebrahimi-Fakhari
- Department of Pediatric Neurology, Saarland University Medical Center, Building 9, Kirrberger Strasse, 66421, Homburg, Saarland, Germany.
| | - Lilian Lisa Mann
- Department of Pediatric Neurology, Saarland University Medical Center, Building 9, Kirrberger Strasse, 66421, Homburg, Saarland, Germany
| | - Martin Poryo
- Department of Pediatric Cardiology, Saarland University Medical Center, Homburg, Germany
| | - Norbert Graf
- Department of Pediatric Oncology and Hematology, Saarland University Medical Center, Homburg, Germany
| | - Rüdiger von Kries
- Division of Epidemiology, Institute of Social Pediatrics and Adolescent Medicine, Ludwig Maximilian's University, Munich, Germany.,German Paediatric Surveillance Unit (ESPED), Coordination Center for Clinical Studies, Heinrich Heine University, Düsseldorf, Germany
| | - Beate Heinrich
- German Paediatric Surveillance Unit (ESPED), Coordination Center for Clinical Studies, Heinrich Heine University, Düsseldorf, Germany
| | - Darius Ebrahimi-Fakhari
- Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Marina Flotats-Bastardas
- Department of Pediatric Neurology, Saarland University Medical Center, Building 9, Kirrberger Strasse, 66421, Homburg, Saarland, Germany
| | - Ludwig Gortner
- Department of Pediatric Neurology, Saarland University Medical Center, Building 9, Kirrberger Strasse, 66421, Homburg, Saarland, Germany
| | - Michael Zemlin
- Department of Pediatric Neurology, Saarland University Medical Center, Building 9, Kirrberger Strasse, 66421, Homburg, Saarland, Germany
| | - Sascha Meyer
- Department of Pediatric Neurology, Saarland University Medical Center, Building 9, Kirrberger Strasse, 66421, Homburg, Saarland, Germany
| |
Collapse
|
6
|
Affiliation(s)
- S. Nasifoglu
- Department of Dermatology; General Hospital Augsburg; Augsburg Germany
| | - B. Heinrich
- Brudler, Heinrich, Bangerter Haematologic-Oncological Practice; Augsburg Germany
| | - J. Welzel
- Department of Dermatology; General Hospital Augsburg; Augsburg Germany
| |
Collapse
|
7
|
Nettesheim S, Kölker S, Karall D, Häberle J, Posset R, Hoffmann GF, Heinrich B, Gleich F, Garbade SF. Incidence, disease onset and short-term outcome in urea cycle disorders -cross-border surveillance in Germany, Austria and Switzerland. Orphanet J Rare Dis 2017; 12:111. [PMID: 28619060 PMCID: PMC5472961 DOI: 10.1186/s13023-017-0661-x] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2017] [Accepted: 05/30/2017] [Indexed: 12/30/2022] Open
Abstract
Background Urea cycle disorders (UCDs) are a group of rare inherited metabolic disorders. Affected individuals often present with hyperammonemic encephalopathy (HE) and have an increased risk of severe neurologic disease and early death. The study aims to provide epidemiologic data and to describe the disease manifestation and short-term outcome. Method Cross-border surveillance of newly diagnosed patients with UCDs - below 16 years of age - was performed from July 2012 to June 2015 in Germany and Austria and from January 2012 to December 2015 in Switzerland. Inquiries were sent monthly to all Pediatric Departments in Germany and Switzerland, and quarterly to the Austrian Metabolic Group. In addition, data were collected via a second source (metabolic laboratories) in all three countries. Results Between July 2012 and June 2015, fifty patients (Germany: 39, Austria: 7, Switzerland: 4) with newly diagnosed UCDs were reported and later confirmed resulting in an estimated cumulative incidence of 1 in 51,946 live births. At diagnosis, thirty-nine patients were symptomatic and 11 asymptomatic [10 identified by newborn screening (NBS), 1 by high-risk-family screening (HRF)]. The majority of symptomatic patients (30 of 39 patients) developed HE with (n = 25) or without coma (n = 5), 28 of them with neonatal onset. Despite emergency treatment 15 of 30 patients with HE already died during the newborn period. Noteworthy, 10 of 11 patients diagnosed by NBS or HRF remained asymptomatic. Comparison with the European registry and network for intoxication type metabolic diseases (E-IMD) demonstrated that cross-national surveillance identified a higher number of clinically severe UCD patients characterized by earlier onset of symptoms, higher peak ammonium concentrations in plasma and higher mortality. Conclusion Cross-border surveillance is a powerful tool to identify patients with UCDs demonstrating that (1) the cumulative incidence of UCDs is lower than originally suggested, (2) the mortality rate is still high in patients with neonatal onset of symptoms, and (3) onset type and peak plasma ammonium concentration predict mortality.
Collapse
Affiliation(s)
- Susanne Nettesheim
- Division of Neuropediatrics and Metabolic Medicine, Center for Child and Adolescent Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany
| | - Stefan Kölker
- Division of Neuropediatrics and Metabolic Medicine, Center for Child and Adolescent Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany
| | - Daniela Karall
- Medical University of Innsbruck, Clinic for Pediatrics I, Inherited Metabolic Disorders, Innsbruck, Austria
| | - Johannes Häberle
- University Children's Hospital Zurich, Division of Metabolism and Children's Research Center, Zurich, Switzerland
| | - Roland Posset
- Division of Neuropediatrics and Metabolic Medicine, Center for Child and Adolescent Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany
| | - Georg F Hoffmann
- Division of Neuropediatrics and Metabolic Medicine, Center for Child and Adolescent Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany
| | - Beate Heinrich
- Erhebungseinheit für Seltene Pädiatrische Erkrankungen in Deutschland, Coordination Center for Clinical Studies, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Florian Gleich
- Division of Neuropediatrics and Metabolic Medicine, Center for Child and Adolescent Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany
| | - Sven F Garbade
- Division of Neuropediatrics and Metabolic Medicine, Center for Child and Adolescent Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany.
| | | |
Collapse
|
8
|
Heinrich B, Klein J, Delic M, Goepfert K, Engel V, Geberzahn L, Lusky M, Erbs P, Preville X, Moehler M. Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes. Onco Targets Ther 2017; 10:2389-2401. [PMID: 28496337 PMCID: PMC5422459 DOI: 10.2147/ott.s126320] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Oncolytic virotherapy is an emerging immunotherapeutic modality for cancer treatment. Oncolytic viruses with genetic modifications can further enhance the oncolytic effects on tumor cells and stimulate antitumor immunity. The oncolytic vaccinia viruses JX-594-GFP+/hGM-CSF (JX-GFP) and TG6002 are genetically modified by secreting granulocyte-macrophage colony-stimulating factor (GM-CSF) or transforming 5-fluorocytosine (5-FC) into 5-fluorouracil (5-FU). We compared their properties to kill tumor cells and induce an immunogenic type of cell death in a human melanoma cell model using SK29-MEL melanoma cells. Their influence on human immune cells, specifically regarding the activation of dendritic cells (DCs) and the interaction with the autologous cytotoxic T lymphocyte (CTL) clone, was investigated. Melanoma cells were infected with either JX-GFP or TG6002 alone or in combination with 5-FC and 5-FU. The influence of viral infection on cell viability followed a time- and multiplicity of infection dependent manner. Combination of virus treatment with 5-FU resulted in stronger reduction of cell viability. TG6002 in combination with 5-FC did not significantly strengthen the reduction of cell viability in this setting. Expression of calreticulin and high mobility group 1 protein (HMGB1), markers of immunogenic cell death (ICD), could be detected after viral infection. Accordingly, DC maturation was noted after viral oncolysis. DCs presented stronger expression of activation and maturation markers. The autologous CTL clone IVSB expressed the activation marker CD69, but viral treatment failed to enhance cytotoxicity marker. In summary, vaccinia viruses JX-GFP and TG6002 lyse melanoma cells and induce additional immunostimulatory effects to promote antitumor immune response. Further investigation in vivo is needed to consolidate the data.
Collapse
Affiliation(s)
- B Heinrich
- First Department of Internal Medicine, University Medical Center Mainz, Mainz, Germany
| | - J Klein
- First Department of Internal Medicine, University Medical Center Mainz, Mainz, Germany
| | - M Delic
- First Department of Internal Medicine, University Medical Center Mainz, Mainz, Germany
| | - K Goepfert
- First Department of Internal Medicine, University Medical Center Mainz, Mainz, Germany
| | - V Engel
- First Department of Internal Medicine, University Medical Center Mainz, Mainz, Germany
| | - L Geberzahn
- First Department of Internal Medicine, University Medical Center Mainz, Mainz, Germany
| | - M Lusky
- Transgene SA, Illkirch-Graffenstaden
| | - P Erbs
- Transgene SA, Illkirch-Graffenstaden
| | | | - M Moehler
- First Department of Internal Medicine, University Medical Center Mainz, Mainz, Germany
| |
Collapse
|
9
|
Mann L, Ebrahimi-Fakhari D, Heinrich B, Flotats-Bastardas M, Gortner L, von Gontard A, Niemcyzk J, Poryo M, Meyer S. [ESPED-Survey: TSC-disease in children and adolescents: preliminary results from a German epidemiological survey]. Wien Med Wochenschr 2016; 167:271-275. [PMID: 27812765 DOI: 10.1007/s10354-016-0522-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2016] [Accepted: 10/03/2016] [Indexed: 11/28/2022]
Abstract
BACKGROUND Tuberous sclerosis complex (TSC) disease is a rare genetic, multi-organ disorder characterized by the occurrence of multiple hamartoma. METHODS In cooperation with ESPED, Germany, a prospective, epidemiological study was performed to assess the incidence of newly diagnosed TSC disease in patients ≤18 years in Germany. Moreover, the following parameters were assessed: 1. Age distribution at initial diagnosis; 2. Percentage of patients with in utero diagnosis of TSC; 3. Detailed description of pathological clinical findings; 4. Results from genetic testing. RESULTS In this one-year interim analysis, 84 electronic questionnaires were received, 17 of which did not contain complete sets of data and were not included in data analysis. Twenty-three of 67 questionnaires did not report TSC patients and 3 reports contained redundant data sets and were excluded. In total, 41 reports were included into data analysis (female: 23; male: 18); median age at first diagnosis was 6 months (range: 0-151 months). The three most common symptoms were: central nervous affection: 31/41 patients ((75.6 %); 29/31 with seizures); rhabdomyoma: in 20/41 (48.8 %); cutaneous affection: hypomelanotic maculae ("white spots"): 20/41 (48.8 %). The three following organ manifestations were seen most often in a comprehensive diagnostic work-up: rhabdomyoma: 23/41 ((56.1 %); cortical dysplasia: 22/41 (53.7 %); "white spots"): 20/41 (48.8 %). In 11/41 patients, cardiac rhabdomyoma were detected by ultrasonography prenatally. In 6 patients, a TSC-2 mutation was found while in 4 patients a TSC-1 mutation was noted; in 1 patient, genetic testing was negative. CONCLUSIONS Based on our preliminary findings, the annual incidence rate for TSC disease is estimated at approximately 1:12,300 live births, but this is a very rough approximation.
Collapse
Affiliation(s)
- Lilian Mann
- Medizinische Fakultät, Universität des Saarlandes Campus Homburg, 66421, Homburg, Deutschland
| | - Daniel Ebrahimi-Fakhari
- Medizinische Fakultät, Universität des Saarlandes Campus Homburg, 66421, Homburg, Deutschland
| | | | - Marina Flotats-Bastardas
- Klinik für Allgemeine Pädiatrie und Neonatologie, TSC-Zentrum Saarland, Sektion Neuropädiatrie, Universitätsklinikum des Saarlandes, 66421, Homburg, Deutschland
| | - Ludwig Gortner
- Klinik für Allgemeine Pädiatrie und Neonatologie, Universitätsklinikum des Saarlandes, 66421, Homburg, Deutschland
| | - Alexander von Gontard
- Klinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum des Saarlandes, 66421, Homburg, Deutschland
| | - Justine Niemcyzk
- Klinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum des Saarlandes, 66421, Homburg, Deutschland
| | - Martin Poryo
- Klinik für Pädiatrische Kardiologie, Universitätsklinikum des Saarlandes, 66421, Homburg, Deutschland
| | - Sascha Meyer
- Klinik für Allgemeine Pädiatrie und Neonatologie, TSC-Zentrum Saarland, Sektion Neuropädiatrie, Universitätsklinikum des Saarlandes, 66421, Homburg, Deutschland.
| |
Collapse
|
10
|
Singer P, Wirth M, Berger I, Heinrich B, Gödicke W, Voigt S, Taube C, Jaross W, Gehrisch S. Long-chain omega 3 fatty acids are the most effective polyunsaturated fatty acids for dietary prevention and treatment of cardiovascular risk factors. Conclusions from clinical studies. World Rev Nutr Diet 2015; 69:74-112. [PMID: 1441585 DOI: 10.1159/000421667] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- P Singer
- Central Institute for Cardiovascular Research, Academy of Sciences, Berlin-Buch, FRG
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Reck M, Thomas M, Schuette W, Kimmich M, Rittmeyer A, Heinrich B, Yurasov S, Zimmermann A, Carter GC, Garon EB, Pérol M. Update REVEL: Eine randomisierte, doppelblinde Phase III Studie von Docetaxel (DOC) und Ramucirumab (RAM; IMC-1121B) versus DOC und Placebo (PL) in der Zweitlinienbehandlung des Nicht-Kleinzelligen Lungenkarzinoms im Stadium IV nach Progression der Erkrankung nach einer Platin-basierten Vortherapie. Pneumologie 2015. [DOI: 10.1055/s-0035-1544764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
12
|
Charlon M, Heinrich B, Matter Y, Couzigné E, Donnio B, Avérous L. Synthesis, structure and properties of fully biobased thermoplastic polyurethanes, obtained from a diisocyanate based on modified dimer fatty acids, and different renewable diols. Eur Polym J 2014. [DOI: 10.1016/j.eurpolymj.2014.10.012] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
13
|
von Minckwitz G, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer JU, Hauschild M, Fehm T, Nekljudova V, Gerber B, Gnauert K, Heinrich B, Prätz T, Groh U, Tanzer H, Villena C, Tulusan A, Liedtke B, Blohmer JU, Kittel K, Mau C, Potenberg J, Schilling J, Just M, Weiss E, Bückner U, Wolfgarten M, Lorenz R, Doering G, Feidicker S, Krabisch P, Deichert U, Augustin D, Kunz G, Kast K, von Minckwitz G, Nestle-Krämling C, Rezai M, Höß C, Terhaag J, Fasching P, Staib P, Aktas B, Kühn T, Khandan F, Möbus V, Solbach C, Tesch H, Stickeler E, Heinrich G, Wagner H, Abdallah A, Dewitz T, Emons G, Belau A, Rethwisch V, Lantzsch T, Thomssen C, Mattner U, Nugent A, Müller V, Noesselt T, Holms F, Müller T, Deuker JU, Schrader I, Strumberg D, Uleer C, Solomayer E, Runnebaum I, Link H, Tomé O, Ulmer HU, Conrad B, Feisel-Schwickardi G, Eidtmann H, Schumacher C, Steinmetz T, Bauerfeind I, Kremers S, Langanke D, Kullmer U, Ober A, Fischer D, Kohls A, Weikel W, Bischoff J, Freese K, Schmidt M, Wiest W, Sütterlin M, Dietrich M, Grießhammer M, Burgmann DM, Hanusch C, Rack B, Salat C, Sattler D, Tio J, von Abel E, Christensen B, Burkamp U, Köhne CH, Meinerz W, Graßhoff ST, Decker T, Overkamp F, Thalmann I, Sallmann A, Beck T, Reimer T, Bartzke G, Deryal M, Weigel M, Huober J, Weder P, Steffens CC, Lemster S, Stefek A, Ruhland F, Hofmann M, Schuster J, Simon W, Kronawitter U, Clemens M, Fehm T, Janni W, Latos K, Bauer W, Roßmann A, Bauer L, Lampe D, Heyl V, Hoffmann G, Lorenz-Salehi F, Hackmann J, Schlag R. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†. Ann Oncol 2014; 25:2363-2372. [PMID: 25223482 DOI: 10.1093/annonc/mdu455] [Citation(s) in RCA: 97] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND The GeparQuinto study showed that adding bevacizumab to 24 weeks of anthracycline-taxane-based neoadjuvant chemotherapy increases pathological complete response (pCR) rates overall and specifically in patients with triple-negative breast cancer (TNBC). No difference in pCR rate was observed for adding everolimus to paclitaxel in nonearly responding patients. Here, we present disease-free (DFS) and overall survival (OS) analyses. PATIENTS AND METHODS Patients (n = 1948) with HER2-negative tumors of a median tumor size of 4 cm were randomly assigned to neoadjuvant treatment with epirubicin/cyclophosphamide followed by docetaxel (EC-T) with or without eight infusions of bevacizumab every 3 weeks before surgery. Patients without clinical response to EC ± Bevacizumab were randomized to 12 weekly cycles paclitaxel with or without everolimus 5 mg/day. To detect a hazard ratio (HR) of 0.75 (α = 0.05, β = 0.8) 379 events had to be observed in the bevacizumab arms. RESULTS With a median follow-up of 3.8 years, 3-year DFS was 80.8% and 3-year OS was 89.7%. Outcome was not different for patients receiving bevacizumab (HR 1.03; P = 0.784 for DFS and HR 0.974; P = 0.842 for OS) compared with patients receiving chemotherapy alone. Patients with TNBC similarly showed no improvement in DFS (HR = 0.99; P = 0.941) and OS (HR = 1.02; P = 0.891) when treated with bevacizumab. No other predefined subgroup (HR+/HER2-; locally advanced (cT4 or cN3) or not; cT1-3 or cT4; pCR or not) showed a significant benefit. No difference in DFS (HR 0.997; P = 0.987) and OS (HR 1.11; P = 0.658) was observed for nonearly responding patients receiving paclitaxel with or without everolimus overall as well as in subgroups. CONCLUSIONS Long-term results, in opposite to the results of pCR, do not support the neoadjuvant use of bevacizumab in addition to an anthracycline-taxane-based chemotherapy or everolimus in addition to paclitaxel for nonearly responding patients. CLINICAL TRIAL NUMBER NCT 00567554, www.clinicaltrials.gov.
Collapse
Affiliation(s)
- G von Minckwitz
- Headquarter, German Breast Group, Neu-Isenburg; Department of Gynaecology and Obstetrics, University Hospital, Frankfurt.
| | - S Loibl
- Headquarter, German Breast Group, Neu-Isenburg
| | - M Untch
- Department of Gynaecology and Obstetrics, Klinikum Berlin-Buch, Berlin
| | - H Eidtmann
- Department of Gynaecology and Obstetrics, University Hospital, Kiel
| | - M Rezai
- Breast Center, Luisenkrankenhaus, Düsseldorf
| | - P A Fasching
- Department of Gynaecology and Obstetrics, University Hospital, Erlangen
| | - H Tesch
- Department of Medical Oncology, Chop GmbH, Frankfurt
| | - H Eggemann
- Department of Gynaecology and Obstetrics, University Hospital, Magdeburg
| | - I Schrader
- Department of Gynaecology and Obstetrics, Henriettenstiftung, Hannover
| | - K Kittel
- Department of Gynaecology and Obstetrics, Praxisklinik, Berlin
| | - C Hanusch
- Department of Gynaecology and Obstetrics, Rot-Kreuz-Klinikum, München
| | - J Huober
- Department of Gynaecology and Obstetrics, University Hospital, Ulm
| | - C Solbach
- Department of Gynaecology and Obstetrics, University Hospital, Frankfurt
| | - C Jackisch
- Department of Gynaecology and Obstetrics, Sana-Klinikum, Offenbach
| | - G Kunz
- Department of Gynaecology and Obstetrics, St Johannes Hospital, Dortmund
| | - J U Blohmer
- Department of Gynaecology and Obstetrics, St Gertrauden-Hospital, Berlin
| | - M Hauschild
- Department of Gynaecology and Obstetrics, Hospital, Rheinfelden
| | - T Fehm
- Department of Gynaecology and Obstetrics, University Hospital, Tübingen
| | | | - B Gerber
- Department of Gynaecology and Obstetrics, University Hospital, Rostock, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Choi EY, Mazur L, Mager L, Gwon M, Pitrat D, Mulatier JC, Monnereau C, Fort A, Attias AJ, Dorkenoo K, Kwon JE, Xiao Y, Matczyszyn K, Samoc M, Kim DW, Nakao A, Heinrich B, Hashizume D, Uchiyama M, Park SY, Mathevet F, Aoyama T, Andraud C, Wu JW, Barsella A, Ribierre JC. Photophysical, amplified spontaneous emission and charge transport properties of oligofluorene derivatives in thin films. Phys Chem Chem Phys 2014; 16:16941-56. [DOI: 10.1039/c4cp01134a] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
We investigate the charge transport, photophysical and amplified spontaneous emission properties of a series of monodisperse solution-processable oligofluorenes functionalized with hexyl chains at the C9 position of each fluorene unit.
Collapse
Affiliation(s)
- E. Y. Choi
- Department of Physics
- CNRS-Ewha International Research Center
- Ewha Womans University
- Seoul, South Korea
| | - L. Mazur
- Institut Parisien de Chimie Moléculaire
- Chimie des Polymères
- Université Pierre et Marie Curie
- UMR 8232
- Ivry, France
| | - L. Mager
- Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS)
- UMR 7504
- CNRS-Université de Strasbourg
- 67034 Strasbourg Cedex 2, France
| | - M. Gwon
- Department of Physics
- CNRS-Ewha International Research Center
- Ewha Womans University
- Seoul, South Korea
| | - D. Pitrat
- Laboratoire de Chimie
- CNRS-UMR 5182
- University of Lyon 1
- Ecole Normale Supérieure de Lyon
- Lyon, France
| | - J. C. Mulatier
- Laboratoire de Chimie
- CNRS-UMR 5182
- University of Lyon 1
- Ecole Normale Supérieure de Lyon
- Lyon, France
| | - C. Monnereau
- Laboratoire de Chimie
- CNRS-UMR 5182
- University of Lyon 1
- Ecole Normale Supérieure de Lyon
- Lyon, France
| | - A. Fort
- Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS)
- UMR 7504
- CNRS-Université de Strasbourg
- 67034 Strasbourg Cedex 2, France
| | - A. J. Attias
- Institut Parisien de Chimie Moléculaire
- Chimie des Polymères
- Université Pierre et Marie Curie
- UMR 8232
- Ivry, France
| | - K. Dorkenoo
- Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS)
- UMR 7504
- CNRS-Université de Strasbourg
- 67034 Strasbourg Cedex 2, France
| | - J. E. Kwon
- Department of Materials Science and Engineering
- Seoul National University
- Seoul, South Korea
| | - Y. Xiao
- Institut Parisien de Chimie Moléculaire
- Chimie des Polymères
- Université Pierre et Marie Curie
- UMR 8232
- Ivry, France
| | - K. Matczyszyn
- Institute of Physical and Theoretical Chemistry
- Wroclaw University of Technology
- 50-370 Wroclaw, Poland
| | - M. Samoc
- Institute of Physical and Theoretical Chemistry
- Wroclaw University of Technology
- 50-370 Wroclaw, Poland
| | - D.-W. Kim
- Department of Physics
- CNRS-Ewha International Research Center
- Ewha Womans University
- Seoul, South Korea
| | - A. Nakao
- Nuclear Spectroscopy Laboratory
- RIKEN Nishina Center for Accelerator-Based Science (RNC)
- Wako, Japan
| | - B. Heinrich
- Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS)
- UMR 7504
- CNRS-Université de Strasbourg
- 67034 Strasbourg Cedex 2, France
| | - D. Hashizume
- Materials Characterization Support Unit
- RIKEN Center for Emergent Matter Science (CEMS)
- Wako, Japan
| | - M. Uchiyama
- Elements Chemistry Laboratory
- RIKEN
- Wako, Japan
- Graduate School of Pharmaceutical Sciences
- The University of Tokyo
| | - S. Y. Park
- Department of Materials Science and Engineering
- Seoul National University
- Seoul, South Korea
| | - F. Mathevet
- Institut Parisien de Chimie Moléculaire
- Chimie des Polymères
- Université Pierre et Marie Curie
- UMR 8232
- Ivry, France
| | - T. Aoyama
- Elements Chemistry Laboratory
- RIKEN
- Wako, Japan
| | - C. Andraud
- Laboratoire de Chimie
- CNRS-UMR 5182
- University of Lyon 1
- Ecole Normale Supérieure de Lyon
- Lyon, France
| | - J. W. Wu
- Department of Physics
- CNRS-Ewha International Research Center
- Ewha Womans University
- Seoul, South Korea
| | - A. Barsella
- Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS)
- UMR 7504
- CNRS-Université de Strasbourg
- 67034 Strasbourg Cedex 2, France
| | - J. C. Ribierre
- Department of Physics
- CNRS-Ewha International Research Center
- Ewha Womans University
- Seoul, South Korea
| |
Collapse
|
15
|
Sun Y, Chang H, Kabatek M, Song YY, Wang Z, Jantz M, Schneider W, Wu M, Montoya E, Kardasz B, Heinrich B, te Velthuis SGE, Schultheiss H, Hoffmann A. Damping in yttrium iron garnet nanoscale films capped by platinum. Phys Rev Lett 2013; 111:106601. [PMID: 25166689 DOI: 10.1103/physrevlett.111.106601] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/07/2012] [Revised: 03/29/2013] [Indexed: 06/03/2023]
Abstract
Strong damping enhancement in nm-thick yttrium iron garnet (YIG) films due to Pt capping layers was observed. This damping is substantially larger than the expected damping due to conventional spin pumping, is accompanied by a shift in the ferromagnetic resonance field, and can be suppressed by the use of a Cu spacer in between the YIG and Pt films. The data indicate that such damping may originate from the ferromagnetic ordering in Pt atomic layers near the YIG/Pt interface and the dynamic exchange coupling between the ordered Pt spins and the spins in the YIG film.
Collapse
Affiliation(s)
- Yiyan Sun
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523, USA
| | - Houchen Chang
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523, USA
| | - Michael Kabatek
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523, USA
| | - Young-Yeal Song
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523, USA
| | - Zihui Wang
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523, USA
| | - Michael Jantz
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523, USA
| | - William Schneider
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523, USA
| | - Mingzhong Wu
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523, USA
| | - E Montoya
- Physics Department, Simon Fraser University, Burnaby, British Columbia, V5A 1S6, Canada
| | - B Kardasz
- Physics Department, Simon Fraser University, Burnaby, British Columbia, V5A 1S6, Canada
| | - B Heinrich
- Physics Department, Simon Fraser University, Burnaby, British Columbia, V5A 1S6, Canada
| | | | - Helmut Schultheiss
- Materials Science Division, Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - Axel Hoffmann
- Materials Science Division, Argonne National Laboratory, Argonne, Illinois 60439, USA
| |
Collapse
|
16
|
Rastei MV, Heinrich B, Gallani JL. Puckering stick-slip friction induced by a sliding nanoscale contact. Phys Rev Lett 2013; 111:084301. [PMID: 24010441 DOI: 10.1103/physrevlett.111.084301] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/28/2013] [Indexed: 06/02/2023]
Abstract
An atomic force microscope reveals that the sliding of a nanotip on a graphite surface occurs through a nanoscale stick-slip mechanism. The angle between the sliding direction and a stiff crystallographic axis determines the periodicity of the slip events defining domains of various friction properties. The experimental data are interpreted using the reaction rate theory, with the energy barrier driven by a local deformation of the surface and a thermally activated relaxation.
Collapse
Affiliation(s)
- M V Rastei
- Institut de Physique et Chimie des Matériaux de Strasbourg, CNRS, Université de Strasbourg, F-67034 Strasbourg, France
| | | | | |
Collapse
|
17
|
Goldstein LJ, Oliveria CT, Heinrich B, Stemmer SM, Mala C, Selder S, Bevan P, Harbeck N. Abstract P5-20-01: A randomized double-blind phase II study of the combination of oral WX-671 plus capecitabine vs. capecitabine monotherapy in first-line HER2− negative metastatic breast cancer (MBC). Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p5-20-01] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: uPA and its inhibitor PAI-1 play a key role in tumor invasion, metastasis and tumor growth. High levels of uPA and PAI-1 in breast tumors are statistically significant prognostic factors of disease-free (DFS) and overall survival (OS), which were validated at the highest level of evidence, as well as predictors for benefit of adjuvant chemotherapy. WX-UK1 is an active site competitive inhibitor of uPA with an inhibition constant in the submicromolar range. WX-671 (upamostat) is an oral prodrug of WX-UK1. In preclinical animal tumor models, both WX-UK1 and WX-671 have been shown to reduce the growth rate of implanted tumors, to inhibit invasion, and reduce metastases. This current proof of concept study is designed to substantiate the anti-metastatic properties of upamostat for patients appropriate for first line therapy for MBC.
Methods: Female patients aged >18, with HER2 negative MBC appropriate for first line monotherapy with capecitabine, with adequate performance status, organ function, bone marrow reserve without brain metastases were eligible. Patients were randomized in a double-blind fashion to receive upamostat (200mg orally daily for 21 days) plus capecitabine (1000 mg/m2 orally twice daily for 14 days) vs. capecitabine (1000 mg/m2 orally twice daily for 14 days) in 3 week treatment cycles until progressive disease or unacceptable toxicity. The primary endpoint is to evaluate the efficacy of the combination of upamostat plus capecitabine compared to monotherapy as assessed by comparison of progression free survival. The secondary objectives are OS, objective response rates, safety and tolerability, and to assess the pharmacokinetics (PK) of upamostat and capecitabine when combined.
Results: Between August 2008 and April 2011,132 patients were enrolled. 17 patients are still receiving treatment. 26% of the patients are characterized as triple negative, 13% as only Estrogen Receptor (ER) positive and 4% as only Progesteron Receptor (PR) positive. 57 % of the patients are ER and PR positive.
Conclusions: Progression free survival, response rates and safety will be reported. This abstract is being submitted as a placeholder. A completed abstract will be submitted when the analyses are completed.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P5-20-01.
Collapse
Affiliation(s)
- LJ Goldstein
- Fox Chase Cancer Center, Philadelphia, PA; Instituto Brasilerio Controle Cancer, Sao Paulo, Brazil; Hamatologisch-Onkologische-Praxis Augsburg, Augsburg, Germany; Rabin Medical Center, Petah Tikva, Israel; Wilex, Munich, Germany; Univeristy of Munich, Munich, Germany
| | - CT Oliveria
- Fox Chase Cancer Center, Philadelphia, PA; Instituto Brasilerio Controle Cancer, Sao Paulo, Brazil; Hamatologisch-Onkologische-Praxis Augsburg, Augsburg, Germany; Rabin Medical Center, Petah Tikva, Israel; Wilex, Munich, Germany; Univeristy of Munich, Munich, Germany
| | - B Heinrich
- Fox Chase Cancer Center, Philadelphia, PA; Instituto Brasilerio Controle Cancer, Sao Paulo, Brazil; Hamatologisch-Onkologische-Praxis Augsburg, Augsburg, Germany; Rabin Medical Center, Petah Tikva, Israel; Wilex, Munich, Germany; Univeristy of Munich, Munich, Germany
| | - SM Stemmer
- Fox Chase Cancer Center, Philadelphia, PA; Instituto Brasilerio Controle Cancer, Sao Paulo, Brazil; Hamatologisch-Onkologische-Praxis Augsburg, Augsburg, Germany; Rabin Medical Center, Petah Tikva, Israel; Wilex, Munich, Germany; Univeristy of Munich, Munich, Germany
| | - C Mala
- Fox Chase Cancer Center, Philadelphia, PA; Instituto Brasilerio Controle Cancer, Sao Paulo, Brazil; Hamatologisch-Onkologische-Praxis Augsburg, Augsburg, Germany; Rabin Medical Center, Petah Tikva, Israel; Wilex, Munich, Germany; Univeristy of Munich, Munich, Germany
| | - S Selder
- Fox Chase Cancer Center, Philadelphia, PA; Instituto Brasilerio Controle Cancer, Sao Paulo, Brazil; Hamatologisch-Onkologische-Praxis Augsburg, Augsburg, Germany; Rabin Medical Center, Petah Tikva, Israel; Wilex, Munich, Germany; Univeristy of Munich, Munich, Germany
| | - P Bevan
- Fox Chase Cancer Center, Philadelphia, PA; Instituto Brasilerio Controle Cancer, Sao Paulo, Brazil; Hamatologisch-Onkologische-Praxis Augsburg, Augsburg, Germany; Rabin Medical Center, Petah Tikva, Israel; Wilex, Munich, Germany; Univeristy of Munich, Munich, Germany
| | - N Harbeck
- Fox Chase Cancer Center, Philadelphia, PA; Instituto Brasilerio Controle Cancer, Sao Paulo, Brazil; Hamatologisch-Onkologische-Praxis Augsburg, Augsburg, Germany; Rabin Medical Center, Petah Tikva, Israel; Wilex, Munich, Germany; Univeristy of Munich, Munich, Germany
| |
Collapse
|
18
|
Heinrich B, From M, Cochran J, Liao LX, Celiński Z, Schneider C, Myrtle K. Studies of Exchange Coupling in Fe (001) Whisker/Cr/Fe Structures using BLS and Rheed Techniques. ACTA ACUST UNITED AC 2012. [DOI: 10.1557/proc-313-119] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
ABSTRACTThe conditions for an almost perfect growth of smooth Cr (001) films on an iron whisker substrate have been investigated by means of reflection high energy electron diffraction (RHEED). The exchange interaction between 20 Monolayer thick Fe (001) films separated from a bulk whisker Fe (001) substrate by a variable number of Cr (001) Monolayers (ML) has been investigated by means of Brillouin light scattering experiments (BLS). These experiments show unambiguously that the exchange coupling strength between the iron film and the iron whisker can be described by a short wavelength oscillatory term superposed on a slowly varying antiferromagnetic background. The BLS data enabled one to separate the bilinear and the biquadratic contributions to the antiferromagnetic exchange coupling terms. Both the bilinear and the biquadratic coupling strengths exhibited a short period oscillatory dependence on the Cr interlayer thickness (∼2 Monolayers). Maxima in the bilinear antiferromagnetic coupling strength occur for an odd number of Cr Monolayers. This observation is not in agreement with first principles calculations. The first phase inversion has been found to occur between 4 and 5 ML of Cr.
Collapse
|
19
|
Heinrich B, Arrott AS, Cochran JF, Urquhart KB, Myrtle K, Celinski Z, Zhong QM. In-Situ Techniques for Studying Epitaxially Grown Layers and Determining their Magnetic Properties. ACTA ACUST UNITED AC 2012. [DOI: 10.1557/proc-151-177] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
ABSTRACTUltrathin films of bcc Fe (001) on Ag (001) and Fe/Ni (001) bilayers on Ag were grown by molecular beam epitaxy. A wide range of surface science tools (RHEED, REELFS, AES, and XPS) were employed to establish the quality of epitaxial growth. Ferromagnetic resonance and Brillouin light scattering were used to extract the magnetic properties. Emphasis was placed on the study of magnetic anisotropies. Large uniaxial anisotropies with the easy axis perpendicular to the film surface were observed in all ultrathin structures studied. In sufficiently thin samples the saturation magnetization was oriented perpendicular to the film surface in the absence of an applied field. It has been demonstrated that in bcc Fe films the uniaxial perpendicular anisotropy originates at the film interfaces. Fe/Ni bilayers were also investigated. Ni grows in the pure bcc structure for the first 3–6ML and then transforms to a new structure which exhibits unique magnetic properties. Transformed ultrathin bilayers possesses large in-plane 4th order anisotropies far surpassing those observed in bulk Fe and Ni. The large 4th order anisotropies originate in crystallographic defects formed during the Ni lattice transformation.
Collapse
|
20
|
Karthaus M, Poddubnaya I, Churilova L, Khasanov R, Veremeychuk T, Rumyantseva E, Garin M, Brichkova O, Heinrich B, Heinemann V. Gemcitabine (G) and cisplatin (C) as first-line treatment of metastatic breast cancer (MBC): Results of phase II trial. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.27_suppl.273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
273 Background: G has been studied in combination with a variety of agents known to be active in cancer. G has a mild toxicity profile. GC is active in various advanced tumors. Splitting of C dose (D 1 + d8) is better tolerated and can be a good alternative to once a cycle in pts with advanced breast cancer. This phase II trial evaluates G (1000 mg/m2) C (35 mg/ m2) d1+8 repeated every 21 d in the 1st-line treatment of metastatic breast cancer (MBC). The primary objective of the study was to determine the objective tumor response rate (ORR) of 1st-line GC in patients with metastatic breast cancer.The one-stage design tested the null hypothesis that the true response rate for this population should be equal to 50% for efficacy. Overall survival (OS), time to progression (TTP) and toxicity were evaluated. Methods: 70 female MBC pts with the median age of 49.8 ys (range 29.6-80.0) were enrolled. Tumor assessment was performed every other cycle by standard criteria including CT or MRI. 67 pts received a total of 310 cycles GC, out of these 54 pts were evaluable for efficacy. Results: Complete and partial responses were observed in 7/54 (13.0%) and 19/54 (35.2%) evaluable pts, respectively with an overall response of 48.2%. Disease stabilization was noticed in 19/54 (35.2%) pts. Progression was observed in 5/54 (9.3%) pts. TTP was 33.9 weeks (95% CI, 23.9-48.0). OS was 84.0 weeks (95% CI, 58.6-119.3). 1-year overall survival rate was 68.4% (95% CI, 53.6-79.3%). Hematological toxicity G4 was neutropenia in 14.9% (10/67), and no G4 thrombocytopenia. Hypotension G4 (1.5%) was the only severe non-hematological toxicity. Conclusions: GC in the first-line treatment of MBC, demonstrated a substantial overall response rate and had a good toxicity profile. GC is a suitable option for first-line MBC in selected pts.
Collapse
Affiliation(s)
- M. Karthaus
- Klinikum Neuperlach, Munich, Germany; Russian Medical Academy for Postgraduate Education, Moscow, Russia; Oncology Dispensary, Barnaul, Russia; Republic Oncology Dispensary, Kazan, Russia; Oncology Dispensary, Murmansk, Russia; Oncology Dispensary, Vladimir, Russia; Russian Cancer Research Center, Moscow, Russia; Oncology Dispensary, Saratov, Russia; Hämatologisch-onkologische-Praxis Augsburg, Augsburg, Germany; Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany
| | - I. Poddubnaya
- Klinikum Neuperlach, Munich, Germany; Russian Medical Academy for Postgraduate Education, Moscow, Russia; Oncology Dispensary, Barnaul, Russia; Republic Oncology Dispensary, Kazan, Russia; Oncology Dispensary, Murmansk, Russia; Oncology Dispensary, Vladimir, Russia; Russian Cancer Research Center, Moscow, Russia; Oncology Dispensary, Saratov, Russia; Hämatologisch-onkologische-Praxis Augsburg, Augsburg, Germany; Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany
| | - L. Churilova
- Klinikum Neuperlach, Munich, Germany; Russian Medical Academy for Postgraduate Education, Moscow, Russia; Oncology Dispensary, Barnaul, Russia; Republic Oncology Dispensary, Kazan, Russia; Oncology Dispensary, Murmansk, Russia; Oncology Dispensary, Vladimir, Russia; Russian Cancer Research Center, Moscow, Russia; Oncology Dispensary, Saratov, Russia; Hämatologisch-onkologische-Praxis Augsburg, Augsburg, Germany; Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany
| | - R. Khasanov
- Klinikum Neuperlach, Munich, Germany; Russian Medical Academy for Postgraduate Education, Moscow, Russia; Oncology Dispensary, Barnaul, Russia; Republic Oncology Dispensary, Kazan, Russia; Oncology Dispensary, Murmansk, Russia; Oncology Dispensary, Vladimir, Russia; Russian Cancer Research Center, Moscow, Russia; Oncology Dispensary, Saratov, Russia; Hämatologisch-onkologische-Praxis Augsburg, Augsburg, Germany; Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany
| | - T. Veremeychuk
- Klinikum Neuperlach, Munich, Germany; Russian Medical Academy for Postgraduate Education, Moscow, Russia; Oncology Dispensary, Barnaul, Russia; Republic Oncology Dispensary, Kazan, Russia; Oncology Dispensary, Murmansk, Russia; Oncology Dispensary, Vladimir, Russia; Russian Cancer Research Center, Moscow, Russia; Oncology Dispensary, Saratov, Russia; Hämatologisch-onkologische-Praxis Augsburg, Augsburg, Germany; Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany
| | - E. Rumyantseva
- Klinikum Neuperlach, Munich, Germany; Russian Medical Academy for Postgraduate Education, Moscow, Russia; Oncology Dispensary, Barnaul, Russia; Republic Oncology Dispensary, Kazan, Russia; Oncology Dispensary, Murmansk, Russia; Oncology Dispensary, Vladimir, Russia; Russian Cancer Research Center, Moscow, Russia; Oncology Dispensary, Saratov, Russia; Hämatologisch-onkologische-Praxis Augsburg, Augsburg, Germany; Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany
| | - M. Garin
- Klinikum Neuperlach, Munich, Germany; Russian Medical Academy for Postgraduate Education, Moscow, Russia; Oncology Dispensary, Barnaul, Russia; Republic Oncology Dispensary, Kazan, Russia; Oncology Dispensary, Murmansk, Russia; Oncology Dispensary, Vladimir, Russia; Russian Cancer Research Center, Moscow, Russia; Oncology Dispensary, Saratov, Russia; Hämatologisch-onkologische-Praxis Augsburg, Augsburg, Germany; Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany
| | - O. Brichkova
- Klinikum Neuperlach, Munich, Germany; Russian Medical Academy for Postgraduate Education, Moscow, Russia; Oncology Dispensary, Barnaul, Russia; Republic Oncology Dispensary, Kazan, Russia; Oncology Dispensary, Murmansk, Russia; Oncology Dispensary, Vladimir, Russia; Russian Cancer Research Center, Moscow, Russia; Oncology Dispensary, Saratov, Russia; Hämatologisch-onkologische-Praxis Augsburg, Augsburg, Germany; Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany
| | - B. Heinrich
- Klinikum Neuperlach, Munich, Germany; Russian Medical Academy for Postgraduate Education, Moscow, Russia; Oncology Dispensary, Barnaul, Russia; Republic Oncology Dispensary, Kazan, Russia; Oncology Dispensary, Murmansk, Russia; Oncology Dispensary, Vladimir, Russia; Russian Cancer Research Center, Moscow, Russia; Oncology Dispensary, Saratov, Russia; Hämatologisch-onkologische-Praxis Augsburg, Augsburg, Germany; Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany
| | - V. Heinemann
- Klinikum Neuperlach, Munich, Germany; Russian Medical Academy for Postgraduate Education, Moscow, Russia; Oncology Dispensary, Barnaul, Russia; Republic Oncology Dispensary, Kazan, Russia; Oncology Dispensary, Murmansk, Russia; Oncology Dispensary, Vladimir, Russia; Russian Cancer Research Center, Moscow, Russia; Oncology Dispensary, Saratov, Russia; Hämatologisch-onkologische-Praxis Augsburg, Augsburg, Germany; Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany
| |
Collapse
|
21
|
Heinrich B, Burrowes C, Montoya E, Kardasz B, Girt E, Song YY, Sun Y, Wu M. Spin pumping at the magnetic insulator (YIG)/normal metal (Au) interfaces. Phys Rev Lett 2011; 107:066604. [PMID: 21902353 DOI: 10.1103/physrevlett.107.066604] [Citation(s) in RCA: 72] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/19/2011] [Indexed: 05/20/2023]
Abstract
Spin injection across the ferrimagnetic insulator (YIG)/normal metal (Au) interface was studied by ferromagnetic resonance. The spin mixing conductance was determined by comparing the Gilbert damping in bare YIG films with those covered by a Au/Fe/Au structure. The Fe layer in Au/Fe/Au acted as a spin sink as displayed by an increased Gilbert damping parameter α compared to that in the bare YIG. In particular, for the 9.0 nm YIG/2.0 nm Au/4.3 nm Fe/6.1 nm Au structure, the YIG and Fe films were coupled by an interlayer exchange coupling, and the exchange coupled YIG exhibited an increased Gilbert damping compared to the bare YIG. This relationship between static and dynamic coupling provides direct evidence for spin pumping. The transfer of spin momentum across the YIG interface is surprisingly efficient with the spin mixing conductance g(↑↓) ≃ 1.2 × 10(14) cm(-2).
Collapse
Affiliation(s)
- B Heinrich
- Physics Department, Simon Fraser University, Burnaby, British Columbia, Canada.
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Wiechno PJ, Chlosta P, Smok-Kalwat J, Pikilel J, Henry DH, Christianson DF, Somer BG, Mellado B, Duran I, Castellano DE, Callies S, Andre V, Hurt K, Lahn MMF, Stöckle M, Reuter C, Heinrich B. Interim results of a randomized phase II study with window-design to evaluate antitumor activity of the survivin antisense oligonucleotide (ASO) LY2181308 in combination with docetaxel for first-line treatment of castrate-resistant prostate cancer (CRPC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4592] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
23
|
Dederke B, Schumann C, Seraphin J, Wagner TOF, Rittmeyer A, Eschenburg H, Harich H, Vehling-Kaiser U, Esser M, Heinrich B. Erlotinib (Tarceva®) in der Routinebehandlung des nicht-kleinzelligen Lungenkarzinoms nach Versagen einer vorangegangenen Chemotherapie. Pneumologie 2011. [DOI: 10.1055/s-0031-1272215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
24
|
Terazzi E, Jensen TB, Donnio B, Buchwalder K, Bourgogne C, Rogez G, Heinrich B, Gallani J, Piguet C. Control of the transition temperatures of metallomesogens by specific interface design: application to Mn12 single molecule magnets. Dalton Trans 2011; 40:12028-32. [DOI: 10.1039/c1dt10908a] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
25
|
Heinemann V, Di Gioia D, Vehling-Kaiser U, Harich HD, Heinrich B, Welt A, Ziske C, Deutsch G, Pihusch R, Kölbl H, Hegewisch-Becker S, Michl M, Stemmler HJ. A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer. Ann Oncol 2010; 22:603-608. [PMID: 20724574 DOI: 10.1093/annonc/mdq409] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND To evaluate the efficacy and safety of oral and i.v. vinorelbine plus trastuzumab as first-line regimen in a patient-convenient application for human epidermal growth factor receptor 2 (HER2)-overexpressing patients with metastatic breast cancer. PATIENTS AND METHODS Forty-two women were enrolled in a multicenter study. The patients received i.v. vinorelbine at a dose of 25 mg/m(2) on day 1 followed by oral vinorelbine at a dose of 60 mg/m(2) on days 8 and 15 in a 3-week cycle. Standard dose trastuzumab was given at 3-week intervals. RESULTS Complete response was observed in 7 patients (18.9%) and partial response in 19 patients (51.4%), for an overall response rate of 70.3% [95% confidence interval (CI) 53.0-84.1]. The disease control rate reached 91.9% (95% CI 78.1-98.3). The median time to progression was 9.3 months, while median overall survival reached 35.6 months. Hematological and non-hematological toxic effects were acceptable with grade 3-4 leukopenia of 14% and neutropenia of 38%; cardiac toxicity did not reach the level of clinical relevance. CONCLUSION The combination of i.v. and oral vinorelbine plus trastuzumab demonstrates high activity and good tolerability in first-line treatment of HER2-overexpressing metastatic breast cancer. In addition, it offers convenience for the patients with only one i.v. treatment every 3 weeks.
Collapse
Affiliation(s)
- V Heinemann
- Medical Department III, University of Munich, Munich.
| | - D Di Gioia
- Medical Department III, University of Munich, Munich
| | | | | | | | - A Welt
- Department of Medicine (Cancer Research), West German Cancer Center, University Hospital Essen, Essen
| | - C Ziske
- Oncological Practice, Troisdorf
| | - G Deutsch
- Department of Gynecology, Diakonissenkrankenhaus Karlsruhe, Karlsruhe
| | | | - H Kölbl
- Department of Gynecology, University of Mainz, Mainz
| | | | - M Michl
- Medical Department III, University of Munich, Munich
| | - H J Stemmler
- Medical Department III, University of Munich, Munich
| |
Collapse
|
26
|
|
27
|
Abstract
At high ambient temperatures, honeybees regulate head teriperature by evaporative cooling of regurgitated honeycrop contents. Thoracic temperature is secondarily stabilized as heat flows from thorax to head by means of passive conduction and physiological facilitation resulting from accelerated blood flow. The mechanism permits flight at the extraordinarily high ambient temperature of 46 degrees C without overheating the head and thorax despite prodigious amounts of heat produced as a by-product of flight metabolism. In contrast, at low ambient temperatures, thoracic rather than head temperature is regulated; no liquid is regurgitated, and the head is heated passively by conduction both in flight and while stationary.
Collapse
|
28
|
Lander F, Heinrich B, Hufnagel M, Flügge K, Kries RV, Berner R. Invasive Infektionen durch Gruppe B-Streptokokken (Streptococcus agalactiae) bei Neugeborenen und jungen Säuglingen in Deutschland – Aktuelle Ergebnisse der laufenden ESPED-Studie. Klin Padiatr 2010. [DOI: 10.1055/s-0030-1261466] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
29
|
Lander F, Heinrich B, Hufnagel M, Flügge K, Kries RV, Berner R. Epidemiologie invasiver Infektionen durch Escherichia coli bei Neugeborenen und jungen Säuglingen in Deutschland – Aktuelle Ergebnisse der laufenden ESPED-Studie. Klin Padiatr 2010. [DOI: 10.1055/s-0030-1261467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
30
|
Göbel U, Heinrich B, Krauth KA, Steingrüber HJ, von Kries R. [Process and outcome quality of the German Paediatric Surveillance Unit (ESPED)]. Klin Padiatr 2010; 222:92-7. [PMID: 20146163 DOI: 10.1055/s-0030-1247587] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
UNLABELLED The German paediatric surveillance unit (ESPED) was founded in 1992 with the objective to generate incidence data and to describe symptoms, diagnostic procedures, therapy and prevention for rare paediatric diseases requiring in hospital treatment. Every month the ESPED office sends a mailing card to the heads of all paediatric departments asking for the incident diagnosis of up to 12 conditions. In 2007 about 96% of the cards are returned. Each condition is represented by a principal investigator. Up till now surveillance of 52 conditions has been performed. Reports on the mailing card prompt immediate mailing of the full questionnaire. For 43 conditions the return rates were in the range of 70-100% and for 7 conditions <70% (unknown 2). The highest return rates were achieved if the principal investigator was supported by staff comprising at least two persons or if the mailing of the questionnaire was handled by the ESPED office. The scientific impact of the ESPED System was assessed by the impact factors of the journals, in which the respective ESPED studies were published. By August 31 (st) 2008 the investigators of 38 studies reported up to 7 publications per conditions surveyed. A total of 104 publications was reported: 27 of these appeared in journals without an impact factor. Among the 77 other publications 10 appeared in journals with an impact factor >10. CONCLUSION Surveillance in ESPED has contributed significantly to high quality research on rare conditions in children.
Collapse
Affiliation(s)
- U Göbel
- ESPED-Geschäftsstelle, Koordinierungszentrum für Klinische Studien, Universitätsklinikum Düsseldorf, Germany
| | | | | | | | | |
Collapse
|
31
|
Abstract
Due to the importance of using up-to-date data in information systems, this article analyzes how the data-quality dimension currency can be quantified. Based on several requirements (e.g., normalization and interpretability) and a literature review, we design a procedure to develop probability-based metrics for currency which can be adjusted to the specific characteristics of data attribute values. We evaluate the presented procedure with regard to the requirements and illustrate the applicability as well as its practical benefit. In cooperation with a major German mobile services provider, the procedure was applied in the field of campaign management in order to improve both success rates and profits.
Collapse
|
32
|
Reimer G, Brudler O, Heinrich B, Bangerter M. [EGFR (epidermal growth factor receptor) inhibitor-associated skin disorders in tumor therapy]. MMW Fortschr Med 2008; 150:37-40. [PMID: 19133368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Affiliation(s)
- G Reimer
- Praxis für Dermatologie und Allergologie Augsburg.
| | | | | | | |
Collapse
|
33
|
Shimizu Y, Heinrich B, Guillon D, Shiro M, Monobe H, Oikawa K. Mesophase semiconductors: design for 3D-mesophases with effective paths for electronic charge hopping. Acta Crystallogr A 2008. [DOI: 10.1107/s0108767308099005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
34
|
Laessig D, Vehling-Kaiser U, Harich HD, Welt A, Heinrich B, Pihusch R, Ziske C, Deutsch G, Hegewisch-Becker S, Heinemann V. Oral and intravenous vinorelbine plus trastuzumab for 1st-line treatment of HER2-overexpressing metastatic breast cancer (MBC). A trial of the german AIO breast cancer group. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.1061] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
35
|
Heinrich B. [Fever--a cardinal symptom in medicine]. MMW Fortschr Med 2008; 150:46-51. [PMID: 18300646 DOI: 10.1007/bf03365280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
|
36
|
Rastei MV, Heinrich B, Limot L, Ignatiev PA, Stepanyuk VS, Bruno P, Bucher JP. Size-dependent surface states of strained cobalt nanoislands on Cu(111). Phys Rev Lett 2007; 99:246102. [PMID: 18233461 DOI: 10.1103/physrevlett.99.246102] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/11/2007] [Indexed: 05/23/2023]
Abstract
Low-temperature scanning tunneling spectroscopy over Co nanoislands on Cu(111) showed that the surface states of the islands vary with their size. Occupied states exhibit a sizable downward energy shift as the island size decreases. The position of the occupied states also significantly changes across the islands. Atomic-scale simulations and ab initio calculations demonstrate that the driving force for the observed shift is related to size-dependent mesoscopic relaxations in the nanoislands.
Collapse
Affiliation(s)
- M V Rastei
- Institut de Physique et Chimie des Matériaux de Strasbourg, UMR 7504, Université Louis Pasteur, F-67034 Strasbourg, France
| | | | | | | | | | | | | |
Collapse
|
37
|
Woltersdorf G, Mosendz O, Heinrich B, Back CH. Magnetization dynamics due to pure spin currents in magnetic double layers. Phys Rev Lett 2007; 99:246603. [PMID: 18233469 DOI: 10.1103/physrevlett.99.246603] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/22/2007] [Indexed: 05/25/2023]
Abstract
The magnetization dynamics in magnetic double layers is affected by spin-pump and spin-sink effects. So far, only the spin pumping and its effect on the magnetic damping has been studied. However, due to conservation of angular momentum this spin current also leads to magnetic excitation of the layer dissipating this angular momentum. In this Letter we use time resolved magneto-optic Kerr effect to directly show the excitation due to the pure spin current. In particular, we observe magnetization dynamics due to transfer of angular momentum in magnetic double layers. In contrast to other experiments where a spin polarized charge current is passed through a nanomagnet, the effects discussed in this Letter are based on pure spin currents without net transfer of electric charge.
Collapse
|
38
|
Fassnacht M, Hahner S, Adam P, Heinrich B, Quinkler M, Stroebel P, Allolio B. Epidermal growth factor receptor (EGFR) as a potential new target in the treatment of patients with adrenocortical carcinoma: Results of pre-clinical studies. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.21025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
21025 Background: Adrenocortical carcinoma (ACC) is a rare malignancy with incompletely understood pathogenesis and poor prognosis. Overexpression of epidermal growth factor receptor (EGFR) has been demonstrated in several tumors and is partly associated with a more aggressive phenotype and a worse prognosis. In addition, targeting the EGFR tyrosine kinase represents a successful new therapeutic strategy, e.g. in non-small cell lung cancer. Therefore, we investigated the role of EGFR in ACC as a potential therapeutic target. Methods: EGFR expression was analyzed by immunohistochemistry in 115 ACCs and 5 normal adrenals using paraffin sections and tissue arrays (scoring of expression: 0–3). Utilizing the clinical data from the German ACC registry, Kaplan Meier survival analyses were performed. In 30 patients the tumor DNA was sequenced for mutations of the “hot spot” exons 19–21 of the EGFR gene. In addition, cells of the ACC cell line NCI-h295 were incubated with the EGFR antibody cetuximab (1–100 μg/ml) and cell proliferation was measured by MTT tests. Results: Immunohistochemistry revealed EGFR expression in 78% of ACCs. In 67/115 (58%) of the ACCs and 0/5 of the normal adrenals the expression level was judged as moderate-to-high (score 2 or 3). However, the expression level did not correlate with the clinical outcome in these patients. In addition, none of the sequenced tumor DNA samples showed a mutation in exons 19–21. Cetuximab exhibited a dose dependent antiproliferative effect in NCI-H295 cells (cell viability: 1μg/ml: 95±2%; 10μg/ml 90±3%*; 100 μg/ml 85±4%* vs untreated control cells: 100±3%; * = p<0.01). Conclusion: EGFR is overexpressed in the majority of ACC. Moreover, in vitro experiments demonstrated that inhibition of EGFR signalling lead to moderate growth inhibition in ACC cells. Therefore, in patients with ACC refractory to established cytotoxic therapies the experimental use of EGFR inhibitors (combined with cytotoxic therapy) seems to be justified. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Fassnacht
- University Hospital of Wuerzburg, Wuerzburg, Germany; Charite Campus Mitte, Berlin, Germany; University of Heidelberg, Mannheim, Germany
| | - S. Hahner
- University Hospital of Wuerzburg, Wuerzburg, Germany; Charite Campus Mitte, Berlin, Germany; University of Heidelberg, Mannheim, Germany
| | - P. Adam
- University Hospital of Wuerzburg, Wuerzburg, Germany; Charite Campus Mitte, Berlin, Germany; University of Heidelberg, Mannheim, Germany
| | - B. Heinrich
- University Hospital of Wuerzburg, Wuerzburg, Germany; Charite Campus Mitte, Berlin, Germany; University of Heidelberg, Mannheim, Germany
| | - M. Quinkler
- University Hospital of Wuerzburg, Wuerzburg, Germany; Charite Campus Mitte, Berlin, Germany; University of Heidelberg, Mannheim, Germany
| | - P. Stroebel
- University Hospital of Wuerzburg, Wuerzburg, Germany; Charite Campus Mitte, Berlin, Germany; University of Heidelberg, Mannheim, Germany
| | - B. Allolio
- University Hospital of Wuerzburg, Wuerzburg, Germany; Charite Campus Mitte, Berlin, Germany; University of Heidelberg, Mannheim, Germany
| |
Collapse
|
39
|
Heinrich B, Hahner S, Adam P, Johanssen S, Quinkler M, Koschker AC, Stroebel P, Marx A, Allolio B, Fassnacht M. Epidermal growth factor receptor (EGFR) as a potential new target in the treatment of patients with adrenocortical carcinoma – results of pre-clinical studies. Exp Clin Endocrinol Diabetes 2007. [DOI: 10.1055/s-2007-972204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
40
|
Guillon D, Heinrich B, Ribeiro AC, Cruz C, Nguyen HT. Thermotropic Lamellar-to-Columnar Phase Transition Exhibited by a Biforked Compound. ACTA ACUST UNITED AC 2006. [DOI: 10.1080/10587259808047105] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- D. Guillon
- a Institut de Physiquet et de Chimie des Matériaux de Strasbourg , Groupe des Matériaux Organiques, 23, rue du Loess, F-67037 , Strasbourg Cedex , France
| | - B. Heinrich
- a Institut de Physiquet et de Chimie des Matériaux de Strasbourg , Groupe des Matériaux Organiques, 23, rue du Loess, F-67037 , Strasbourg Cedex , France
| | - A. C. Ribeiro
- a Institut de Physiquet et de Chimie des Matériaux de Strasbourg , Groupe des Matériaux Organiques, 23, rue du Loess, F-67037 , Strasbourg Cedex , France
- b Centro de Fisica da Matéria Condensada , Av. Prof. Gama Pinto 2, 1699 , Lisboa Codex , Portugal
| | - C. Cruz
- b Centro de Fisica da Matéria Condensada , Av. Prof. Gama Pinto 2, 1699 , Lisboa Codex , Portugal
| | - H. T. Nguyen
- c Centre de Recherche Paul Pascal , Avenue A. Schweitzer, 33 600 , Pessac , France
| |
Collapse
|
41
|
Heinrich B, Guillon D. Tilt Angle Variation as a Function of Chain Length and Temperature in the Smectic C Phases of p, Alkoxyphenyl-p, Alkoxybenzoates. ACTA ACUST UNITED AC 2006. [DOI: 10.1080/10587259508030990] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- B. Heinrich
- a Institut de Physique et Chimie des Matériaux de Strasbourg, Groupe des Matériaux Organiques , 23, rue due Loess, B.P. 20CR, 67037 , STRASBOURG Cedex , France
| | - D. Guillon
- a Institut de Physique et Chimie des Matériaux de Strasbourg, Groupe des Matériaux Organiques , 23, rue due Loess, B.P. 20CR, 67037 , STRASBOURG Cedex , France
| |
Collapse
|
42
|
Affiliation(s)
- C. Cruz
- a IST-UTL , Av. Rovisco Pais, 1096 , Lisboa Codex
- b CFMC-UL , Av. Prof. Gama Pinto, 2, 1699 , Lisboa Codex , Portugal
| | - J. L. Gallani
- c IPCMS-GMO , 23 rue du Loess, BP 20CR, F-67037 , Strasburg , Cedex , France
| | - B. Heinrich
- c IPCMS-GMO , 23 rue du Loess, BP 20CR, F-67037 , Strasburg , Cedex , France
- d School of Chemistry, University of Exeter , Stocker Road, EXETER , EX4 4QD , England
| | - D. W. Bruce
- d School of Chemistry, University of Exeter , Stocker Road, EXETER , EX4 4QD , England
| | - D. Guillon
- c IPCMS-GMO , 23 rue du Loess, BP 20CR, F-67037 , Strasburg , Cedex , France
| |
Collapse
|
43
|
Fluegge K, Siedler A, Heinrich B, Schulte-Moenting J, Moennig MJ, Bartels DB, Dammann O, von Kries R, Berner R. Incidence and clinical presentation of invasive neonatal group B streptococcal infections in Germany. Pediatrics 2006; 117:e1139-45. [PMID: 16682492 DOI: 10.1542/peds.2005-2481] [Citation(s) in RCA: 76] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
OBJECTIVE Streptococcus agalactiae (group B Streptococcus) is an important cause of morbidity and mortality in newborn infants. So far, there have been no published data on the incidence, morbidity, and mortality of invasive neonatal group B Streptococcus infections in Germany. METHODS A prospective active surveillance study involving all of the pediatric hospitals, which reported their cases to the German Pediatric Surveillance Unit, and all of the microbiological laboratories serving pediatric hospitals, which reported their cases to the Laboratory Sentinel Group at Robert Koch Institute Berlin, was conducted between 2001 and 2003. Capture-recapture analysis was used to evaluate the completeness of reported neonatal invasive group B Streptococcus infections. RESULTS We collected and analyzed data from 347 and 360 infants with invasive group B Streptococcus infection during the first 3 months of life, as reported by pediatricians to the German Pediatric Surveillance Unit and microbiologists to the Robert Koch Institute Berlin, respectively. Using capture-recapture analysis, we calculated an incidence of 0.47 per 1000 live births. Nearly 60% of the infants suffered from early-onset disease, and 16% of these presented with meningitis. In contrast, 61.8% of infants with late-onset disease presented with meningitis. Prematurity was present in 22.4% of early-onset disease and 39.7% of late-onset disease cases, respectively. A high proportion of infants suffered from sequelae because of group B Streptococcus infection at the time of discharge from the hospital. Most common sequelae were hydrocephalus and cerebral seizure. Case fatality rate was 4.3%. CONCLUSIONS This study, which is the first to provide information on the current national incidence and morbidity of invasive group B Streptococcus infection in Germany, demonstrates remarkable country-specific variation in comparison with other European countries, which gather data in a similar fashion. Therefore, the importance of country-specific prevention guidelines has to be stressed.
Collapse
Affiliation(s)
- Kirsten Fluegge
- Department of Pediatrics and Adolescent Medicine, University Hospital Freiburg, Freiburg, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Klusmann A, Heinrich B, Stöpler H, Gärtner J, Mayatepek E, Von Kries R. A decreasing rate of neural tube defects following the recommendations for periconceptional folic acid supplementation. Acta Paediatr 2005; 94:1538-42. [PMID: 16303691 DOI: 10.1080/08035250500340396] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
BACKGROUND/AIM Neural tube defects (NTDs) are the most common birth defects, resulting in severe mortality and morbidity. In 1995, the supplementation of folic acid periconceptionally was officially recommended in Germany. The impact of the recommendations on the rate of NTDs was assessed. METHODS An active surveillance system was established in the northern Rhine area. From 1996, all departments of obstetrics were asked to report cases of NTDs in all abortions, live births and stillbirths. Compliance with the recommendations was evaluated in a sample of mothers who delivered at the Department of Obstetrics of Düsseldorf University in 2001. RESULTS From 1996-2003, 520 NTDs were reported. Compared to the rate of NTDs in 1996 (10.5/10,000), the average incidence in the years 1997 to 2003 dropped (6.8/10,000). The intake of folic acid, as recommended, was low among the general population (21.1%). CONCLUSION Active surveillance data on the rate of NTDs are compatible with the maximum decrease of about 20% to be expected from data on the implementation of the recommendations. A much greater decrease in NTDs should be the challenge for the future.
Collapse
Affiliation(s)
- Anne Klusmann
- Department of General Paediatrics, Children's Hospital, Heinrich Heine University, Düsseldorf, Germany.
| | | | | | | | | | | |
Collapse
|
45
|
Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 2005; 15:219-25. [PMID: 16026983 DOI: 10.1016/j.breast.2005.04.017] [Citation(s) in RCA: 125] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2004] [Revised: 04/04/2005] [Accepted: 04/13/2005] [Indexed: 11/20/2022] Open
Abstract
The intention of this retrospective analysis was to describe the characteristics of patients with brain metastasis (BM) receiving trastuzumab for HER2 overexpressing metastatic breast cancer (MBC). A specific focus was the relation of BM occurrence to remission status of visceral disease during trastuzumab treatment. Patients with MBC presenting between March 2000 and May 2004 were included in this retrospective analysis. HER2 overexpression was determined by immunohistochemistry (IHC; DAKO Hercep Test). Trastuzumab was applied at a loading dose of 4 mg/kg and a maintenance dose of 2 mg/kg. Among 136 HER2 overexpressing patients (DAKO score 3+), 42 patients with BM were identified during follow-up (30.9%). Negative hormone receptor expression (estrogen receptor (ER) and progesterone receptor (PgR)) correlated with incidence of BM (42.8% vs. 23.4%; P=0.01). There was no correlation of the development of BM with regard to tumor grading and patient age. In patients who developed BM, the median interval between visceral and brain metastasis was 14 months (range 0-69 months). At the time BM was diagnosed, 14 out of 42 patients responded to trastuzumab-based treatment schedules (OR: 33.3%, 95% CI 18.5-48.2%). Median survival from diagnosis of BM was 13 months (range 0-60 months). The median overall survival calculated from first diagnosis of metastasis was not significantly shorter in patients with BM than in patients without BM (37 vs. 47 months; P=0.07 log rank). Trastuzumab is highly effective for the treatment of liver and lung metastasis in HER2 overexpressing patients, while it is apparently ineffective for treating or preventing BM. Since one third of HER2 overexpressing patients with MBC developed BM despite effective trastuzumab treatment, new treatment strategies and closer surveillance may be warranted for these patients.
Collapse
Affiliation(s)
- H J Stemmler
- Medical Department III, University of Munich, Grosshadern, Germany.
| | | | | | | | | | | |
Collapse
|
46
|
Woltersdorf G, Buess M, Heinrich B, Back CH. Time resolved magnetization dynamics of ultrathin Fe(001) films: spin-pumping and two-magnon scattering. Phys Rev Lett 2005; 95:037401. [PMID: 16090769 DOI: 10.1103/physrevlett.95.037401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/19/2004] [Indexed: 05/03/2023]
Abstract
The time-resolved magnetic response of ultrathin epitaxial Fe(001) films grown on GaAs(001) and covered by Au, Pd, and Cr capping layers was investigated by time and spatially resolved Kerr effect measurements. The magnetization was excited by an in-plane magnetic field pulse using the transient internal field generated at a Schottky barrier while the wavelength of the excitation (resonant mode) was roughly 4 microm. Each of the three cap layers affected the spin relaxation in a unique way. Au cap layers resulted in the bulk Gilbert damping of the Fe film. Pd cap layers caused an additional Gilbert damping due to spin-pump or spin-sink effects. Cr cap layers lead to a strong extrinsic damping which can be described by two-magnon scattering. In this case the strength of the extrinsic damping can be controlled by a field induced shift of the spin wave manifold with respect to the excited k vector.
Collapse
Affiliation(s)
- G Woltersdorf
- Simon Fraser University, 8888 University Drive, Burnaby, British Columbia V5A 1S6, Canada
| | | | | | | |
Collapse
|
47
|
Engel L, Gupta BBP, Lorenzkowski V, Heinrich B, Schwerdtle I, Gerhold S, Holthues H, Vollrath L, Spessert R. Fos-related antigen 2 (Fra-2) memorizes photoperiod in the rat pineal gland. Neuroscience 2005; 132:511-8. [PMID: 15802201 DOI: 10.1016/j.neuroscience.2004.12.014] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/16/2004] [Indexed: 11/29/2022]
Abstract
As the physiological role of fos-related antigen-2 (Fra-2) is largely unknown and since the pineal plays an important role in the photoperiodic control of the body, we have tested the hypothesis that Fra-2 expression is photoperiod-dependent and may be involved in imprinting photoperiod on the pineal gland and the body as a whole. To this end, we have investigated Fra-2 mRNA expression and Fra-2 protein expression under various light/dark (LD) cycles. A clear nocturnal increase occurs for both monitored parameters under all photoperiodic conditions studied. The level of Fra-2 protein expression clearly depends on photoperiod, because the amount of protein at dark onset and during the night negatively correlates with the length of the photoperiod. Further, high-phosphorylated Fra-2 isoforms are abundant under all photoperiods tested, with the exception of LD 20:4. Because Fra-2 phosphorylation depends on cGMP, a depressed cGMP response to adrenergic stimulation under LD 20:4 appears to explain this finding. We conclude that photoperiod is imprinted on Fra-2 in terms of both protein amount and protein phosphorylation in the rat pineal gland. This imprinting becomes fully manifest after about 7 days only, suggesting that a number of altered photoperiodic cycles are required for pineal Fra-2 to "learn" that the photoperiod has changed. Reportedly, Fra-2 limits expression of the enzyme iodothyronine deiodinase type II, which catalyzes the intracellular deiodination of thyroxine prohormone to the active 3,3',5-triiodothyronine. We have found that the extent of Fra-2 expression inversely correlates with the dII gene response to cAMP; hence the photoperiodic regulation of Fra-2 may affect the body by changing pineal thyroid hormone metabolism.
Collapse
Affiliation(s)
- L Engel
- Department of Anatomy, Johannes Gutenberg University, Saarstrasse 19-21, D-55099 Mainz, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Stemmler J, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V. Brain metastases (BM) in patients treated with trastuzumab for HER2 overexpressing metastatic breast cancer (MBC): Incidence and survival. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.1568] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. Stemmler
- Klin Grosshadern, Medcl Clinic III, Munich, Germany; Klin Grosshadern, Dept of Gynecology, Munich, Germany; Oncological Practice, Augsburg, Germany
| | - S. Kahlert
- Klin Grosshadern, Medcl Clinic III, Munich, Germany; Klin Grosshadern, Dept of Gynecology, Munich, Germany; Oncological Practice, Augsburg, Germany
| | - W. Siekiera
- Klin Grosshadern, Medcl Clinic III, Munich, Germany; Klin Grosshadern, Dept of Gynecology, Munich, Germany; Oncological Practice, Augsburg, Germany
| | - M. Untch
- Klin Grosshadern, Medcl Clinic III, Munich, Germany; Klin Grosshadern, Dept of Gynecology, Munich, Germany; Oncological Practice, Augsburg, Germany
| | - B. Heinrich
- Klin Grosshadern, Medcl Clinic III, Munich, Germany; Klin Grosshadern, Dept of Gynecology, Munich, Germany; Oncological Practice, Augsburg, Germany
| | - V. Heinemann
- Klin Grosshadern, Medcl Clinic III, Munich, Germany; Klin Grosshadern, Dept of Gynecology, Munich, Germany; Oncological Practice, Augsburg, Germany
| |
Collapse
|
49
|
Stamm C, Tudosa I, Siegmann HC, Stöhr J, Dobin AY, Woltersdorf G, Heinrich B, Vaterlaus A. Dissipation of spin angular momentum in magnetic switching. Phys Rev Lett 2005; 94:197603. [PMID: 16090212 DOI: 10.1103/physrevlett.94.197603] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/18/2004] [Indexed: 05/03/2023]
Abstract
Applying one ultrashort magnetic field pulse, we observe up to 10 precessional switches of the magnetization direction in single crystalline Fe films of 10 and 15 atomic layers. We find that the rate at which angular momentum is dissipated in uniform large angle spin precession increases with time and film thickness, surpassing the intrinsic ferromagnetic resonance spin lattice relaxation of Fe by nearly an order of magnitude.
Collapse
Affiliation(s)
- C Stamm
- Stanford Linear Accelerator Center, California 94309, USA.
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Böttcher J, Pfeil A, Heinrich B, Lehmann G, Petrovitch A, Hansch A, Heyne JP, Mentzel HJ, Malich A, Hein G, Kaiser WA. Digital radiogrammetry as a new diagnostic tool for estimation of disease-related osteoporosis in rheumatoid arthritis compared with pQCT. Rheumatol Int 2005; 25:457-64. [PMID: 15761729 DOI: 10.1007/s00296-004-0560-z] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2004] [Accepted: 11/12/2004] [Indexed: 01/01/2023]
Abstract
OBJECTIVES To investigate the potential of a new osteogeometric technology based on digital X-ray radiogrammetry (DXR) as a diagnostic tool for quantification of severity-dependent osteoporosis, and to distinguish between inflammation-mediated and corticoid-induced variations of bone mineralisation in patients suffering from rheumatoid arthritis. METHODS Ninety-six patients (duration of disease: <18 months) underwent retrospective calculations of bone mineral density (DXR-BMD) and metacarpal index (MCI) by DXR, which were calculated from plain radiographs of the non-dominant hand. For comparison, pQCT-calculated BMD (total, cortical-subcortical and trabecular partition of bone tissue) was done on the distal radius. Severity was classified using Ratingen Score by two independent radiologists, and divided into three main groups. In addition, the patients were separated into those with corticoid medication (n=44; 5 mg/day over a half year period) and a control group (n=52) without any corticoid therapy. RESULTS Correlations between DXR-BMD and MCI versus pQCT parameters were all significant (0.36<R<0.71; p<0.01), independent of corticoid therapy. Only in the group without corticoid application, the correlation between DXR-BMD and pQCT-BMD (cortical) showed no significant association. For patients with corticoid therapy, our data revealed the lowest correlation coefficient between DXR parameters and pQCT-BMD (trabecular). Without a difference in comparison to corticoid therapy, the significant relative decrease of BMD estimated by DXR between the highest and lowest score was between 11.1% and 14.3% and for MCI between 15.8% and 17.8%. The also significant relative decrease of trabecular BMD using pQCT varied from 10.3% to 16.9%, whereas no significant results could be verified for pQCT-BMD (cortical and total). CONCLUSIONS Digital radiogrammetry can precisely estimate severity-dependent cortical reduction of bone mineral density in patients suffering from rheumatoid arthritis both with and without corticoid therapy, and seems to be able to distinguish the side effects of antirheumatic treatment from the disease-related periarticular bone loss. The detection and quantification of periarticular osteoporosis by DXR could be an important diagnostic tool in early rheumatoid arthritis.
Collapse
Affiliation(s)
- J Böttcher
- Institute of Diagnostic and Interventional Radiology, Friedrich-Schiller-University Jena, Erlanger Allee 101, 07747, Jena, Germany.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|